Clinical Trials
38 trialsTARSARC
Institut Bergonié
Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma
H. Lee Moffitt Cancer Center and Research Institute
GEMMK
Royal Marsden NHS Foundation Trust
ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer
Washington University School of Medicine
A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
Esperas Pharma Inc.
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
Cyteir Therapeutics, Inc.
Nab-paclitaxel in Combination with Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors
Emory University
Dendritic Cell Vaccine for Children and Adults With Sarcoma
University of Miami
Phase 3 Study to Treat Patients With Soft Tissue Sarcomas
ImmunityBio, Inc.
A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors
Hutchmed
Decitabine and Gemcitabine for Pancreatic Cancer and Sarcoma
University of Iowa
A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects
Sierra Oncology LLC - a GSK company
A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma
Gradalis, Inc.
GemTax
University of Pittsburgh
A Study of Eribulin With Gemcitabine in Patients With Advanced Liposarcoma or Leiomyosarcoma
Yonsei University
ANNOUNCE 2
Eli Lilly and Company
Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma
OHSU Knight Cancer Institute
Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma
Presage Biosciences
A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas
Massachusetts General Hospital
Alimta Plus Gemcitabine for Advanced Sarcoma
Columbia University
A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma
Medical University of South Carolina
SOURCE
Morphotek
Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas
University of Iowa
Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors
Masonic Cancer Center, University of Minnesota
Gemcitabine With or Without Docetaxel as Second-Line Therapy in Treating Patients With Metastatic or Relapsed, Unresectable Uterine or Soft Tissue Leiomyosarcoma
UNICANCER
A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors
Altor BioScience
Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma
University of Vermont
PP-Gemcitabine & External Beam Radiation-Sarcomas
M.D. Anderson Cancer Center
Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes
Memorial Sloan Kettering Cancer Center
Gemcitabine Plus Rapamycin Versus Gemcitabine to Treat Advanced Soft Tissue Sarcoma
Grupo Espanol de Investigacion en Sarcomas
Phase IB Study of Gemcitabine, Docetaxel and Bevacizumab in Patients With Soft Tissue Sarcoma
New Mexico Cancer Research Alliance
Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma
GOG Foundation
STS
National Health Research Institutes, Taiwan
Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors
Dartmouth-Hitchcock Medical Center
Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma
Memorial Sloan Kettering Cancer Center
Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing's Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma
Sarcoma Alliance for Research through Collaboration
Study of Gemcitabine and Vinorelbine in Soft Tissue Sarcomas
Dana-Farber Cancer Institute
Comparison of Gemcitabine v. Gemcitabine Plus Docetaxel in Unresectable Soft Tissue Sarcoma
Memorial Sloan Kettering Cancer Center